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Citrullination-acetylation interplay guides E2F-1
activity during the inflammatory response
Fatemeh Ghari,1 Anne-Marie Quirke,2 Shonagh Munro,1 Joanna Kawalkowska,2 Sarah Picaud,3 Joanna McGouran,4*
Venkataraman Subramanian,5 Aaron Muth,5 Richard Williams,2 Benedikt Kessler,4 Paul R. Thompson,5
Panagis Fillipakopoulos,3,6 Stefan Knapp,3† Patrick J. Venables,2 Nicholas B. La Thangue1‡
Peptidyl arginine deiminase 4 (PAD4) is a nuclear enzyme that converts arginine residues to citrulline. Although
increasingly implicated in inflammatory disease and cancer, the mechanism of action of PAD4 and its functionally
relevant pathways remains unclear. E2F transcription factors are a family of master regulators that coordinate gene
expression during cellular proliferation and diverse cell fates. We show that E2F-1 is citrullinated by PAD4 in inflam-
matory cells. Citrullination of E2F-1 assists its chromatin association, specifically to cytokine genes in granulocyte
cells. Mechanistically, citrullination augments binding of the BET (bromodomain and extra-terminal domain) family
bromodomain reader BRD4 (bromodomain-containing protein 4) to an acetylated domain in E2F-1, and PAD4 and
BRD4 coexist with E2F-1 on cytokine gene promoters. Accordingly, the combined inhibition of PAD4 and BRD4
disrupts the chromatin-bound complex and suppresses cytokine gene expression. In the murine collagen-induced
arthritis model, chromatin-bound E2F-1 in inflammatory cells and consequent cytokine expression are diminished
upon small-molecule inhibition of PAD4 and BRD4, and the combined treatment is clinically efficacious in
preventing disease progression. Our results shed light on a new transcription-based mechanism that mediates
the inflammatory effect of PAD4 and establish the interplay between citrullination and acetylation in the control
of E2F-1 as a regulatory interface for driving inflammatory gene expression.
INTRODUCTION
Peptidyl arginine deiminases (PADs) are a family of five enzymes that
mediate hydrolytic deimination (citrullination) of arginine residues.
PAD4 is a nuclear member of the family and has been reported to
be highly expressed in granulocytes, various cancer types, and pluri-
potent stem cells (1, 2). Hypercitrullination of histones is associated
with the release of neutrophil extracellular traps (NETs) as part of
the innate immune response and opening of chromatin in pluripotent
stem cells. More specific transcriptional regulatory roles have also
been ascribed to PAD4, in relation to both citrullination of specific
histone residues and other cellular substrates (3, 4). The growing
interest in PAD enzymes as pharmacological targets reflects the in-
creasingly prominent role that they have been reported to play in
the context of inflammatory disorders (particularly rheumatoid ar-
thritis) and also cancer.
The E2F family of transcription factors, although historically
connected with cell cycle control, is involved with regulating diverse
cellular outcomes, including apoptosis, differentiation, metabolism,
and inflammation (5, 6). However, the mechanisms that underpin
and guide the diverse biological roles of E2F-1 have yet to be identi-
fied, although insights from arginine methylation suggest that post-
translational modifications are deterministic. Thus, it is known that
methylation in an arginine-rich region influences cell viability or cell
death, reflective of the type of methylation event that occurs; PRMT1
(protein arginine methyltransferase 1)–mediated methylation aug-
ments apoptosis, contrasting with PRMT5-mediated methylation,
which renders E2F-1 with growth-promoting activity (7).
Because citrullination occurs on arginine residues (8), we reasoned
that PAD4 might influence the biological output of E2F-1 if function-
ally important arginine residues were to be modified. Here, we show
that E2F-1 is citrullinated by PAD4 in inflammatory cells, where it
augments the chromatin association of E2F-1 to cytokine genes. Sig-
nificantly, the BET (bromodomain and extra-terminal domain) bro-
modomain family protein BRD4 (bromodomain-containing protein
4) binds to acetylated lysine residues in E2F-1, and PAD4 regulates
the association between E2F-1 and BRD4. Our results show the crucial
regulatory interplay between citrullination and acetylation during the
inflammatory response and its role in dictating the biological outcome
of E2F activity.
RESULTS
Successful PAD4-mediated citrullination of recombinant and endoge-
nous E2F-1 was demonstrated in vitro, both biochemically (Fig. 1A,
lane 7) and in U2OS cells (Fig. 1B). The comparison of N-terminal (1 to 194)
and C-terminal (194 to 437) derivatives (fig. S1A) indicated that the N-
terminal region of E2F-1 is more susceptible to citrullination than the
C-terminal region (Fig. 1C). Arginine (R) residues 109 and 127 were
identified by mass spectrometry as the predominant sites of citrullina-
tion (fig. S1, B and C), although site-directed mutagenesis implied that
R111/R113 could also be involved (fig. S1D). Accordingly, E2F-1 and
PAD4 were shown to interact in cells (Fig. 1D), principally through
the N-terminal region of E2F-1 (fig. S2A). In a gene reporter assay,
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Fig. 1. PAD4-mediated citrullination of E2F-1 augments its transcriptional activity. (A) In vitro citrullination of GST (glutathione S-transferase)–E2F-1by
Flag-PAD4, where recombinant GST–E2F-1 (1 mg) was incubatedwith Flag-PAD4 (1 mg). Lanes 1 to 7 were in the presence of CaCl2, and lane 8 in the absence of
CaCl2. The arrow points to citrullinated GST-E2F-1. AMC, anti-modified citrulline (Millipore); IB, immunoblot. (B) Citrullination of E2F-1 in U2OS cells, transfected
with HA (hemagglutinin)–PAD4 (2 mg). The lysatewas incubatedwith 4mMCaCl2 and 2mMdithiothreitol (DTT). E2F-1 (C20) and rabbit immunoglobulin G (IgG)
antibodies were used for immunoprecipitation (IP). (C) Citrullunation of N-terminal domain of E2F-1 in U2OS cells, transfected with Flag–E2F-1 (1 mg) and HA-
PAD4 (2mg)and treatedwithA23187 (5mM,30min). Flag-agarosebeadswereused for immunoprecipitation.DCE2F-1: 1 to194,DNE2F-1: 194 to437. (D) Interaction
betweenHA–E2F-1 and Flag-PAD4 in Flag-PAD4.pTRE and pTRE empty vector cell lines transfectedwith pcDNA or HA–E2F-1 (1 mg). Flag-agarose beadswere
used for immunoprecipitation. (E) Relative luciferase reporter comparing HA–E2F-1 wild-type (WT) and R4K activity in U2OS cells transfected with HA–E2F-
1 WT or R4K mutant (R109K/R111K/R113K/R127K) (100 ng), Flag-PAD4 (300 ng), p73 luciferase reporter (100 ng), and b-gal (150 ng) plasmid. The luciferase
reporter signal was normalized to b-gal reading. (F) Accompanying immunoblot ± SD. *P < 0.05. (G) Quantitative polymerase chain reaction (qPCR) analysis
comparing FlagDC E2F-1WT and R4K relative promoter occupancy inU2OS cells transfectedwith FlagDC E2F-1WTor R4Kmutant (R109/R111/R113/R127) (1 mg)
and HA-PAD4 (2 mg). Flag antibody was used for ChIP. (H) Accompanying immunoblot ± SD. *P < 0.05. (I) ChIP analysis in doxycycline-inducible Flag-PAD4.
pTRE cells {treated with or without doxycycline (1 mg/ml) [P4(+) and P4(−), respectively]}, measuring PAD4 promoter occupancy in nontargeting (NT) versus
E2F-1 siRNA (30 nM)–transfected cells, and presented as visualized on ethidium bromide–stained gel. NS, nonspecific. (J) Accompanying immunoblot.
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using the promoter region taken from established E2F target genes (in-
cluding TP73 and CDC6), exogenous PAD4 increased E2F-1 activity
(fig. S2B), whereas PAD4 inhibition reduced E2F-1 activity (fig.
S2D) using the PAD4-specific inhibitor TDFA (Thr-Asp-F-amidine)
(9) (but not the inactive analog TDHA). Furthermore, the noncitrul-
linated R4K E2F-1 mutant derivative (R109K/R111K/R113K/R127K;
see fig. S1A) was not affected by PAD4 relative to wild-type E2F-1
(Fig. 1E). Quantitative measurements of E2F-1 binding to its target
gene promoters by chromatin immunoprecipitation (ChIP) revealed
that PAD4 enhanced the chromatin association of E2F-1 but not
the R4K mutant (Fig. 1G and fig. S2F). PAD4 was itself recruited to
E2F-1 target genes, in an E2F-1–dependent manner, because E2F-1 de-
pletion using small interfering RNA (siRNA) diminished PAD4
binding (Fig. 1I). We therefore conclude that PAD4 can enhance
the activity and DNA binding properties of E2F-1.
We surmised that PAD4-dependent citrullination of E2F-1 might
be involved in regulating a subgroup of E2F target genes, to which end
we performed transcript profiling in U2OS cells depleted of E2F-1 and
PAD4 (Fig. 2A). Pathway enrichment analysis using Gene Set Enrich-
ment Analysis (GSEA) (10) revealed significant down-regulation of
immune response upon both E2F-1 and PAD4 depletion (Fig. 2A).
Furthermore, many of the co-regulated genes were involved in the in-
flammatory response when analyzed by PANTHER (Protein Analysis
Through Evolutionary Relationships) (11) (fig. S3, A and B), and the
E2F DNA binding motif was enriched in the promoter region of many
of these genes as determined by CENTDIST (12) (fig. S3, C and D).
Given previous reports for the involvement of E2F-1 (6) and PAD4
(3) in inflammation, we reasoned that PAD4-mediated citrullination
of E2F-1 may regulate inflammatory gene expression.
HL60 cells are myeloid leukemic cells that can differentiate to gran-
ulocytes with dimethyl sulfoxide (DMSO) or all-trans-retinoic acid
(ATRA) (13). Consistent with previous reports, we observed a robust
induction of PAD4 expression in HL60 cells differentiated into gran-
ulocytes (14) (Fig. 2B and fig. S4A), with both PAD4 and E2F-1 demon-
strating nuclear localization (fig. S4B). In granulocyte-differentiated
HL60 cells, we observed an interaction between endogenous E2F-1
and PAD4 (Fig. 2C and fig. S4C), and E2F-1 exhibited increased levels
of citrullination (Fig. 2D). We investigated the recruitment of E2F-1 to
the candidate inflammatory genes TNFa (tumor necrosis factor–a),
CCL3 [chemokine (C-C motif) ligand-3], and IL-1b (interleukin-1b)
because they have previously been shown to be up-regulated in differ-
entiated HL60 cells (15) and are known E2F-1 target genes (6). We ob-
served strong chromatin binding of E2F-1 to the promoters of these
cytokine genes in differentiated cells (Fig. 2E, lane 3 versus lane 7), but
a decrease in promoter occupancy of pRB (retinoblastoma protein)
(Fig. 2E, lane 4 versus lane 8), which negatively regulates E2F-1–dependent
transcription (16). Increasing levels of E2F-1 on the TNFa
promoter were also detected in HL60 cells cotreated with DMSO
and TNFa (fig. S4D), which coincided with increased PAD4 activ-
ity, because citrullination of histone 3 (H3) (8) was enhanced under
these conditions (fig. S4E). Crucially, treatment of differentiated
HL60 cells with either the pan-PAD inhibitor BB-Cl-amidine
(17) (Fig. 2F) or the PAD4-specific inhibitor GSK484 (18) (Fig. 2H)
prevented E2F-1 recruitment to several cytokine gene promoters,
thus implying that PAD4 is responsible for targeting E2F-1 to in-
flammatory genes.
We then investigated the mechanism through which PAD4 aug-
ments E2F-1 activity. Because certain bromodomain reader proteins
participate in inflammatory gene expression (19), we reasoned that re-
cruitment of bromodomains may influence E2F-1 activity during the
inflammatory response. We screened a large collection of bromodo-
mains for binding to E2F-1 peptides and identified the BET family,
including the two bromodomains of BRD4 [bromodomain 1 (BD1)
and BD2], as putative readers of acetylated E2F-1 (Fig. 3A). We
focused on BRD4 because it is involved in modulating immune re-
sponse gene expression (20), it is known to bind dual/polyacetyla-
tion residues (21) (rendering interplay with proximal citrulline marks
possible), and its recognition of E2F-1 had not been previously ex-
plored. The interaction between E2F-1 and both bromodomains of
BRD4 was confirmed in cells (Fig. 3B) and was dependent on the
acetylated lysine residues in E2F-1, because E2F-1 K3R, a mutant de-
rivative lacking the sites of lysine acetylation (22) (fig. S1A), could not
interact with BRD4 (fig. S4F). We found that BRD4 can interact with
E2F-1 on cytokine gene promoters (Fig. 3D) in differentiated HL60
cells and endogenous E2F-1 immunoprecipitated BRD4 (Fig. 3C)
when using double ChIP. Moreover, the BET inhibitor JQ1 (23)
was seen to disrupt the E2F-1/BRD4 complex on promoters (Fig. 3,
E and F) and in cells (fig. S4G), suggesting that BRD4 interacts with
E2F-1 via its bromodomains and drives the expression of inflamma-
tory genes.
Having established that PAD4 is important for directing E2F-1 in-
flammatory gene expression and, further, that BRD4 reads E2F-1 acet-
ylation on inflammatory gene promoters, we surmised that interplay
might occur between citrullination and acetylation marks in regulating
the inflammatory role of E2F-1. This idea was also suggested from the
SPOT array, where an enhanced interaction between E2F-1 peptides
and BET bromodomains was apparent when a citrulline flanked an
acetyl modification (fig. S4H). To test this idea, we treated differen-
tiated HL60 cells with BB-Cl-amidine and monitored the interaction
between E2F-1 and BRD4. Significantly, BB-Cl-amidine treatment re-
duced the level of the chromatin-bound E2F-1/BRD4 complex as
measured by double ChIP (Fig. 3G and fig. S4I), and in U2OS cells
treated with BB-Cl-amidine, a reduced interaction between E2F-1 and
BD1 bromodomain of BRD4 was evident (Fig. 3J). Thereafter, we
measured the expression level of cytokine genes regulated by E2F-1
in cells treated with BB-Cl-amidine and JQ1. Whereas BB-Cl-amidine
and JQ1 reduced cytokine expression in cells treated with each com-
pound alone, the combined treatment was able to reduce the expres-
sion even further (Fig. 4A).
These results implied a functional interplay between citrullination
and lysine acetylation in regulating E2F-1–dependent inflammatory
gene expression. We inquired whether similar effects could be recapi-
tulated in vivo in animal models of inflammation and chose to study
collagen-induced arthritis (CIA) (24). We treated arthritic mice with
JQ1, BB-Cl-amidine, or both inhibitors together and monitored any
effect on paw swelling. We used a dose of each compound (JQ1,
5 mg/kg; BB-Cl-amidine, 1 mg/kg) that, when administered alone,
had a modest effect on disease progression (Fig. 4C). As a control,
we administered a high dose of JQ1 (10 mg/kg), which, as expected
(25), was seen to effectively control paw swelling (Fig. 4C). Crucially,
when the two subtherapeutic doses of BB-Cl-amidine and JQ1 (5 or
1 mg/kg) were administered in combination, a marked reduction in
clinical symptoms was observed (Fig. 4D).
ChIP analysis on spleen tissue (used as a surrogate tissue source)
illustrated that E2F-1 binding to TNFa promoter is diminished in
JQ1/BB-Cl-amidine–cotreated mice relative to untreated CIA mice
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Fig. 2. PAD4 regulates the recruitment of E2F-1 to cytokine gene promoters. (A) U2OS cells were transfected with nontargeting, E2F-1, or PAD4 siRNA
(50 nM). The transcript profilewas analyzed using IlluminaHumanHT12 v4.0 gene expression array. Transcripts for E2F-1 andPAD4 siRNA (E2F-1si and PAD4si)
groups were normalized to nontargeting group and analyzed using GSEA. GSEA revealed down-regulation of immune system (green line) with both E2F-1
and PAD4 siRNAs. The black bars on the far right represent the genes that contribute to the plot. NES, normalized enrichment score. P value <0.01 and false
discovery rate <0.05, *P<0.05, **P<0.01. GAPDH, glyceraldehydephosphate dehydrogenase. (B) Expression of PAD4 in granulocyte-differentiatedHL60 cells
treated with 1% DMSO, ATRA (1 mM), or TPA (12-O-tetradecanoylphorbol 13-acetate) (10 ng/ml) for 48 hours. (C) Interaction between E2F-1 and PAD4 in
DMSO-differentiated HL60 cells treated with 1%DMSO for 48 hours and immunoprecipitated using PAD4 or rabbit IgG antibodies. (D) Citrullination of E2F-1
in DMSO-differentiated HL60 cells. Lysates were incubated with CaCl2 (4 mM) and DTT (2 mM) and immunoprecipitated using E2F-1 (C20) or rabbit IgG
antibodies. (E) ChIP analysis in undifferentiated (-) or DMSO-differentiated (D) HL60 cells. E2F-1 (C20), pRb (IF8), PAD4, and rabbit/mouse IgG antibodies were
used for ChIP and presented as visualized on ethidiumbromide–stainedgel. (F to I) qPCR analysis inDMSO-differentiatedHL60 cellsmeasuring E2F-1 binding
to inflammatory genepromoters, treatedwith LPS (lipopolysaccharide; L) (100 ng/ml, 3 hours) and the pan-PAD inhibitor BB-Cl-amidine (10mM, 6hours) (F) or
the selective PAD4 inhibitor GSK484 (10 mM, 16 hours) (H), with accompanying immunoblots ± SD (G and I). *P < 0.05, **P < 0.01. Relative E2F-1 protein levels
decrease twofold uponBB-Cl-amidine treatment (as quantified by ImageJ), whereas relative E2F-1 promoter occupancy on TNFa promoter decreases fivefold
upon BB-Cl-amidine treatment.
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Fig. 3. E2F-1 interacts with BRD4 on cytokine gene promoters. (A) Heat map of bromodomain binding to acetylated E2F-1 peptides (sequence:
113-RHPGKGVKSPGEKSR-127). The bromodomains are structurally subgrouped into eight families (I to VIII) (21), and the multiple domains of a given
bromodomain protein are represented by numbers in brackets. (B) Interaction between HA–E2F-1 and Flag-BD1/BD2 in human embryonic kidney
(HEK) 293T cells transfected with HA–E2F-1 (1 mg) and Flag-BD1 or Flag-BD2 (2 mg) (BD 1 and BD 2 of BRD4, respectively). Flag-agarose beads were
used for immunoprecipitation. (C) Interaction between E2F-1 and BRD4 in DMSO-differentiated HL60 cells. E2F-1 (C20) or rabbit IgG antibodies were
used for immunoprecipitation. (D to I) qPCR double ChIP analysis of BRD4/E2F-1 interaction in DMSO-differentiated HL60 cells challenged with LPS
(100 ng/ml, 3 hours) (D), treated with JQ1 (5 mM, 4 hours) (E and F), or BB-Cl-amidine (2.5 mM, 16 hours) (G), with accompanying immunoblot ± SD (H and I).
*P < 0.05, **P < 0.01. (J) Interaction between His-BD1 and E2F-1 from U2OS cells treated with JQ1 (5 mM) or BB-Cl-amidine (5 mM) for 16 hours. The cell
lysates were incubated with His-tagged BD1 of BRD4 and subject to Ni-agarose immunoprecipitation.
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Fig. 4. Additive immunosuppressive effects of PAD4 and BRD4 inhibition. (A and B) Quantitative reverse transcription–PCR (qRT-PCR) analysis of cy-
tokine transcript levels in DMSO-differentiated HL60 cells, treatedwith LPS (100 ng/ml, 3 hours), JQ1 (100 nM, 16 hours), and BB-Cl-amidine (2.5 mM, 16 hours)
where indicated (J, JQ1; B, BB-Cl-amidine) (A), with accompanying immunoblot ± SD (B). *P< 0.05, **P<0.01, ***P<0.001. (C andD) Clinical scores for arthritic
paw swelling (n = 7 for each treatment) in DBA/1mice treated with vehicle, BB-Cl-amidine (1 mg/kg), JQ1 (1, 5, or 10 mg/kg), or combinations of, for 10 days
from the onset of symptoms. ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001. (E) qPCR ChIP analysis of E2F-1 promoter occupancy in murine spleen cells, collected
from DBA/1 mice with CIA comparing vehicle and combination treatments. Enrichment of E2F-1 on mouse TNFa gene promoter expressed relative to IgG
control. ±SD. *P<0.05. (F) qRT-PCR analysis of TNFa transcript levels inmurine spleen cells ± SD. **P<0.01, ***P<0.001. (G) Secreted levels of TNFa and IL-6 in
murine inguinal lymphnodes ± SEM. *P<0.05. (H) E2F-1 and IgG control immunohistochemistry staining of vehicle- anddrug-treated paws. The arrows point
to cells in the biopsy positively stained for E2F-1. (I) Model: PAD4-mediated citrullination targets E2F-1 to inflammatory genes, where E2F-1 interacts with
BRD4 to drive inflammatory gene expression.
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(Fig. 4E), with this coinciding with reduced TNFa transcript levels in
the spleen (Fig. 4F). Furthermore, the level of proinflammatory cyto-
kines TNFa and IL-6 measured in the inguinal lymph nodes was re-
duced with the combination treatment to a level comparable to the
treatment with high dose of JQ1 (10 mg/kg) (Fig. 4G). This was
consistent with immunohistochemistry pathology examination on
paw tissue, which found that the high levels of E2F-1 in the arthritic
joints were very much reduced levels in JQ1- or BB-Cl-amidine–
treated mice (Fig. 4H). We therefore conclude that the JQ1/BB-Cl-
amidine combined treatment reduces the chromatin association of
E2F-1 in clinical disease, which reflects reduced cytokine expression
and alleviation of clinical symptoms in the CIA mice.
CONCLUSION
Our results show that PAD4 citrullinates E2F-1 and highlight a novel
role for the PAD4–E2F-1 axis in inflammatory gene expression. Pre-
vious studies have shown E2F-1 recruitment to the promoters of sev-
eral inflammatory genes (6), and in vivo E2F-1 has been demonstrated
to regulate the systemic response to LPSs (26). PAD4 has also been
reported to regulate the expression of cytokine genes (3), and itself
becomes activated downstream of various inflammatory stimuli
(27). Our results provide clarity on a mechanism and pathway
through which PAD4 augments the inflammatory response, where
E2F-1 recruitment to cytokine genes is regulated by PAD4-mediated
citrullination. Furthermore, we identified the BRD4 bromodomain
protein as a reader of acetylation marks on E2F-1 during the inflam-
matory response, which acts together with citrullination to regulate
E2F-1 activity. Accordingly, by studying CIA in mice, we highlight
the possibility of combining small-molecule inhibitors of PAD4 and
BRD4 for treating chronic inflammatory disease, although we recog-
nize that we cannot rule out pathways other than E2F-1 contributing
to the observed effects in vivo. Our results bear on the role of reg-
ulatory arginines in dictating the biological outcome of E2F-1.
Asymmetric methylation on R109 is particularly important for ap-
optosis (7), and this same residue is citrullinated by PAD4. Thus,
by virtue of the citrullination event, PAD4 could hinder apoptosis
driven by E2F-1 while augmenting its role in the inflammatory re-
sponse (Fig. 4I). More generally, our study highlights interplay be-
tween citrullination and acetylation as a regulatory interface for
guiding gene expression.
MATERIALS AND METHODS
Cell culture and compound treatments
U2OS and HL60 cell lines were obtained from the American Type
Culture Collection. They were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM) and RPMI-1640 medium (Sigma), respective-
ly, supplemented with 10% (v/v) fetal calf serum (FCS) (Biosera) and
1% (v/v) penicillin-streptomycin (pen-strep) (Gibco). Stable Tet-On
cell lines expressing inducible Flag-PAD4 were maintained in DMEM
supplemented with 5% (v/v) Tet-negative FCS, G418 (100 mg/ml)
(Clontech), 0.3% hygromycin (Clontech), and 1% (v/v) pen-strep.
Doxycycline (1 mg/ml) was used to induce PAD4 expression in
Flag-PAD4.pTRE cells. HL60 cells were differentiated into granulocyte-
like cells upon treatment with 1% DMSO (tissue culture grade, Sigma)
or 1 mM ATRA for 48 to 72 hours. They were differentiated into mac-
rophage/monocyte-like cells upon treatment with 10 nM TPA for 48 to
72 hours. The expression of CD11B cell surface marker was used to con-
firm differentiation. Given the report that a higher percentage of HL60
cells are responsive to differentiation by DMSO than ATRA (13), DMSO
treatment was used for this study. Where indicated, cells were treated
with LPS (100 ng/ml) or TNFa (10 ng/ml) for 3 hours. TDFA and
GSK484 are selective PAD4 inhibitors, BB-Cl-amidine is a pan-
PAD inhibitor (particularly of isoforms 2 and 4), and JQ1 is a se-
lective BET inhibitor.
Antibodies
PAD4 (ab128086 and ab50247, Abcam), HA (MMS-101R, Covance),
Flag (F3165, Sigma), AMC antibody kit (17-347, Millipore), E2F-1
(KH95 and C20, Santa Cruz Biotechnology), BRD4 (ab128874, Abcam),
b-actin (A2228, Sigma), pRB (IF8, Santa Cruz Biotechnology), CD11B
(ab75476, Abcam), mouse and rabbit secondary antibodies (GE
Healthcare), and HA or Flag antibody-coupled agarose beads (Sigma)
were used.
RNA isolation and PCR
RNA was extracted from cells using TRIzol reagent (Life Technologies)
in accordance with the manufacturer’s guidelines. Reverse transcription
was preformed using SuperScript III Reverse Transcriptase (Life Tech-
nologies), and the complementary DNA (cDNA) was used as template
in PCR [using Paq5000 DNA Polymerase (Agilent Technologies)] or
qRT-PCR [using Brilliant III SYBRMaster Mix (Agilent Technologies)].
For qRT-PCR analysis, transcript levels were normalized to house-
keeping gene GAPDH. The primer sequences used are as follows:
E2F-1, AAGCCCTGTCAGAAATCCAG (forward) and AGGCCCTC-
GACTACCACTT (reverse); GAPDH, ACCTTGCCCACAGCC-
TTGGC (forward) and ATCATCCCTGCCTCTACTGG (reverse);
TNFa (human), CGCCGTCTCCTACCAGACCAAGGTCAAC (for-
ward) and ATGATCCCAAAGTAGACCTGCCCAGACTCG (reverse);
TNFa (mouse), TACTGAACTTCGGGGTGATTGGTCC (forward)
and CAGCCTTGTCCCTTGAAGAGAACC (reverse); IL-1b, AAC-
CTATCTTCTTCGACACATGGGATAACG (forward) and
CAAGGCCACAGGTATTTTGTCATTACTTTC (reverse); CCL3,
CCTTGCTGTCCTCCTCTGCACCATGGCTCT (forward) and
GGTCGCTGACATATTTCTGGACCCACTCCT (reverse); and PAD4,
CATGTTCCACCACTTGAAGG (forward) and TCACCTACCA-
CATCAGGCAT (reverse).
DNA plasmid transfection
Plasmids of interest were transfected into cells using GeneJuice
Transfection Reagent (Invitrogen) in accordance with the manufac-
turer’s guidelines.
Small interfering RNA
siRNA of interest was transfected into cells using Oligofectamine Trans-
fection Reagent (Life Technologies) in accordance with the manufacturer’s
guidelines. E2F-1 siRNA sequence: AACUCCUCGCAGAUCGUCAUC;
PAD4 siRNA sequence: GGUCCUGCUACAAACUGUUTT; nontarget-
ing sequence: Dharmacon NT3 control siRNA
Immunoblotting
Cells were lysed in modified radioimmunoprecipitation assay lysis
buffer {150 mM NaCl, 50 mM tris-HCl (pH 7.5), 1% NP-40, 0.1%
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deoxycholic acid, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO3, and pro-
tease inhibitor cocktail [leupeptin (0.5 mg/ml ), pepstatin (0.5 mg/ml),
and aprotonin (0.5 mg/ml)]} and loaded using SDS loading dye
[62.5 mM tris-HCl (pH 6.8), 25% (v/v) glycerol, 2% (w/v) SDS,
5% (v/v) b-mercaptoethanol, and 0.0625% (w/v) bromophenol blue]
for gel electrophoresis (SDS–polyacrylamide gel electrophoresis).
Coimmunoprecipitation
Cell lysates were incubated with the antibody of interest (1 to 2 mg) for
1 hour overnight (O/N) at 4°C with gentle rotation. IgA- or IgG-agarose
beads (Sigma) were added to the extracts and incubated at 4°C for
1 hour to allow antibody-bead coupling. The beads were washed sev-
eral times with IP wash buffer [50 mM tris-HCl (pH 7.4), 150 mM
NaCl, 0.1% Igepal CA-630/NP-40, 1 mM EDTA, 1 mM NaF, 1 mM
Na3VO3, and protease inhibitor cocktail], and the protein complexes
bound to the antibody-agarose beads were eluted by adding SDS
loading dye.
Luciferase reporter assay
Cells transfected with E2F-1 gene promoter-luciferase construct,
E2F-1/PAD4, and b-gal plasmids were lysed with Reporter Lysis Buffer
(Promega). Luciferase reporter readings were read and normalized to
b-gal assay values {b-gal buffer [0.2 M Na2PO4 (pH 7.2), 2 mM
MgCl2, 0.7% b-mercaptoethanol, and 0.44 M ortho-nitrophenyl-
b-galactopyranoside]}.
Chromatin immunoprecipitation
Cells were cross-linked with formaldehyde (1%, 10 min) and lysed
with ChIP lysis buffer I [5 mM tris-HCl (pH 8.0), 85 mM KCl,
0.5% Igepal CA-630, and protease inhibitor cocktail], followed by
ChIP lysis buffer II [10 mM tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1% Igepal CA-630, 1% deoxycholate (DOC), 0.1%
SDS, and protease inhibitor cocktail]. The lysates were sonicated
to shear the chromatin to fragment sizes between 200 and 1000 base
pairs, precleared using IgG antibodies and protein A and G agarose
beads, and incubated with the antibody of interest O/N. The protein
complex–bound beads were washed with Buffer I [20 mM tris-HCl
(pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-
100, and protease inhibitor cocktail], Buffer II [20 mM tris-HCl
(pH 8.0), 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-
100, and protease inhibitor cocktail], Buffer III [10 mM tris-HCl
(pH 8.0), 250 mM LiCl, 1 mM EDTA, 1% Igepal CA-630, 1%
DOC, and protease inhibitor cocktail], and TE (tris-EDTA) buffer
[10 mM tris-HCl (pH 7.4), 1 mM EDTA, and protease inhibitor
cocktail]. The protein-chromatin complexes were eluted from
beads using elution buffer (1% SDS and 0.1 M NaHCO3) and were
incubated with Proteinase K (40 mg/ml) and RNAse A (20 mg/ml)
and reverse cross-linked at 65°C O/N. DNA was purified using the
Qiagen DNA purification kit. The double ChIP experiments were
performed in two sequential steps, where the chromatin immunopre-
cipitated from the primary ChIP was used as the starting material for
the secondary ChIP.
The ChIP primer sequences are as follows: E2F-1, AG-
GAACCGCCGCCGTTGTTCCCGT (forward) and GCTGCC-
TGCAAAGTCCCGGCCACT (reverse); albumin, TGGGGTTG-
ACAGAAGAGAAAAGC (forward) and TACATTGACAAGG-
TCTTGTGGAG (reverse); TNFa (human), CGATGGAGAAGA-
AACCGAGACAGAAGGTG (forward) and AGTTGCTTCTC-
TCCCTCTTAGCTGGTCCTC (reverse); TNFa (mouse), CGATGGA-
GAAGAAACCGAGACAGA (forward) and CTCCTGGCT-
AGTCCCTTGCTGTCCTC (reverse); IL-1b, GTCATATCAATTTA-
TAGTCCCACGCGTAAT (forward) andCTCACACCCCAGATAAA-
GAGATAACTTGTT (reverse); CCL3, GTCTGAAACCAGCTC-
TCCTCTTTATAGGCA (forward) and GGACTGACTAAGAA-
TAGCCTTGGGTTGACA (reverse); CDC6, GGCCTCACAGC-
GACTCTAAGA (forward) and CTCGGACTCACCACAAGC
(reverse);TP73,TGAGCCATGAAGATGTGCGAG(forward)andGCTGCT-
TATGGTCTGATGCTTATG (reverse); cyclin A, CTGCT-
CAGTTTCCTTTGGTTTACC (forward) and CAAAGACGCCCA-
GAGATGCAG (reverse); and TK (thymidine kinase), TCCCGGATTC-
CTCCCACGAG (forward) and TGCGCCTCCGGGAAGTTCAC
(reverse).
In vitro and in-cell citrullination
Active Flag-PAD4 enzyme was purified from HEK293T cells trans-
fected with Flag-PAD4 plasmids. The lysates were immunoprecipi-
tated using Flag-agarose beads, and the enzyme was released from
beads using Flag-peptide elution. In vitro citrullination was set up
by incubating 0.1 to 1 mg of Flag-PAD4 with 1 to 2 mg of substrate
in 20 ml of buffer composed of 500 mM tris-HCl (pH 7.4), 5 mM
DTT, and 10 mM CaCl2, at 37°C for 1 hour. GST tag alone was
used as the negative control, and calf thymus histones were used
as a positive control for PAD4-mediated citrullination. The reaction
was stopped by the addition of SDS loading buffer and analyzed by
immunoblotting using the AMC kit (Millipore). For in-cell citrullination
assays, the cells were treated with 5 mM A23187 for 30 min, or the
lysate was treated with 4 mM CaCl2 and 2 mM DTT for 30 min.
Drugs for in vivo injection
Stock solutions of BB-Cl-amidine and JQ1 were dissolved in DMSO
(Sigma). Before injection, 5 ml of the stock solutions was diluted in
95 ml of 10% (w/v) hydroxypropyl-b-cyclodextrin (Sigma) [prepared
in sterile nuclease free water (Promega)], such that the final volume
injected into each mouse was 100 ml and the overall DMSO concen-
tration was 5% (v/v).
Mass spectrometry
Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
was performed as previously described (28).
CIA in DBA/1 mice
Arthritis was induced in male DBA/1 mice as previously described
(24). Briefly, bovine collagen was purified from articular cartilage
and dissolved in 0.1 M acetic acid. Ten- to 12-week-old male DBA/
1 mice (Harlan UK) received one subcutaneous 100-ml injection of
200 mg of bovine type II collagen in complete Freund’s adjuvant (Difco,
BD Biosciences) at the base of the tail and on the flank. After immu-
nization, the mice were monitored daily for signs of arthritis. Once a
mouse showed signs of arthritis, it was recruited to a therapy group
and monitored daily. Arthritis severity was scored as follows: 0 =
normal, 1 = slight swelling and/or erythema, 2 = pronounced swelling,
3 = ankylosis. All four limbs were scored, giving a maximum possible
score of 12 per mouse. Seven mice (n = 7) were used for each treat-
ment group. All procedures were performed according to the guide-
lines of the Animals (Scientific Procedures) Act 1986 and the approval
of the UK Home Office (project license PPL7335).
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Cell proliferation ex vivo and cytokine detection
Inguinal lymph node cells were cultured for 48 hours in the presence
of anti-CD3e (0.1 mg/ml) (clone: 145-2C11) (eBioscience) or bovine
type II collagen (50 mg/ml). Cytokines were detected in lymph node
culture supernatants using the Meso Scale Discovery platform ac-
cording to the manufacturer’s instructions.
SPOT array
E2F-1 peptides were synthesized on cellulose membrane as previously
described (21). Briefly, membranes carrying E2F-1 peptides with mod-
ified lysine (acetylation) and arginine (citrullination) residues were
blocked with 5% (w/v) bovine serum albumin (BSA) in 0.3% Tween
20 phosphate-buffered saline (PBST) for 8 hours at room temperature
(RT) and incubated with 1 mM recombinant His-tagged bromodo-
main at 4°C O/N. The following day, the membranes were washed
with PBST buffer and incubated with horseradish peroxidase–
conjugated anti-His antibody (Abcam) in 2.5% BSA in PBST for
1 hour at RT. The membranes were then incubated with Pierce
ECL Western Blotting Substrate (Thermo Scientific) for 2 min, and
luminescence from the membranes was read and captured using the
ImageQuant Las 4000 camera.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/2/2/e1501257/DC1
Fig. S1. Mapping the sites of citrullination on E2F-1.
Fig. S2. PAD4 augments E2F-1 activity and DNA binding affinity.
Fig. S3. Transcripts overlapping between E2F-1 siRNA– and PAD4 siRNA–treated groups show
enrichment of immune response pathways.
Fig. S4. E2F-1 is recruited to inflammatory gene promoters.
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